Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.50 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 14/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.47 |
| ▸ | ABL2 | P42684 | 2/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.47 |
| ▸ | FADS1 | O60427 | 2/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | FBP1 | P09467 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7496462 | 0.89 | TTBK1 (0.51) | TTBK1TTBK2EGFRABL1ABL2 | |
| SCHEMBL4767556 | 0.88 | EGFR (0.51) | TTBK1TTBK2EGFRABL1ABL2 | |
| SCHEMBL4766930 | 0.85 | KDR (0.54) | TTBK1TTBK2EGFRABL1ABL2 | |
| Hydrochloric Acid SCHEMBL4764268 | 0.85 | KDR (0.54) | TTBK1TTBK2EGFRABL1ABL2 | |
| SCHEMBL7498310 | 0.80 | TTBK1 (0.61) | TTBK1TTBK2EGFRABL1ABL2 | |
| SCHEMBL4764732 | 0.79 | TTBK1 (0.60) | TTBK1TTBK2EGFRABL1ABL2 | |
| SCHEMBL7498340 | 0.79 | TTBK1 (0.60) | TTBK1TTBK2EGFRABL1ABL2 | |
| SCHEMBL7495114 | 0.78 | TTBK1 (0.56) | TTBK1TTBK2EGFRABL1ABL2 | |
| SCHEMBL7498456 | 0.78 | TTBK1 (0.56) | TTBK1TTBK2EGFRABL1ABL2 | |
| SCHEMBL4352904 | 0.78 | TTBK1 (0.51) | TTBK1TTBK2EGFRABL1ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6180636-B1 | USED TO INHIBIT THE TYROSINE KINASE ACTIVITY OF THE RECEPTOR FOR THE EPIDERMAL GROWTH FACTOR AND C-ERBB2 KINASE AND CAN BE USED AS ANTITUMOR AGENTS | NOVARTIS AG (CH) | 2001-01-30 | — | — | US | claimed |
| EP-0938486-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | Novartis AG (CH) | 1999-09-01 | — | — | EP | claimed |
| WO-1998007726-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1998-02-26 | — | — | WO | claimed |
| EP-0938486-B1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| US-6180636-B1 | USED TO INHIBIT THE TYROSINE KINASE ACTIVITY OF THE RECEPTOR FOR THE EPIDERMAL GROWTH FACTOR AND C-ERBB2 KINASE AND CAN BE USED AS ANTITUMOR AGENTS | NOVARTIS AG (CH) | 2001-01-30 | — | — | US | disclosed |
| EP-0938486-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | Novartis AG (CH) | 1999-09-01 | — | — | EP | disclosed |
| WO-1998007726-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1998-02-26 | — | — | WO | disclosed |